Literature DB >> 17091278

[Diagnostic work-up of bone metastases of genitourinary tumors and their treatment with bisphosphonates. Interdisciplinary consensus conference, Frankfurt, 2006].

L Weissbach1.   

Abstract

The diagnostic algorithm in cases of suspected bone metastases of genitourinary tumors still starts with a scintigraphic examination. Osseous metastases of hormone-refractory prostate cancer require treatment with zoledronic acid. A potential indication is a hormone-sensitive status. Nephrotoxic substances should not be administered simultaneously. To avoid osteonecrosis of the jaw, prior dental examination, oral hygiene, and if necessary dental reconstruction are recommended. Bisphosphonates can be combined with radiation therapy and chemotherapy; additional administration of calcium and vitamin D is not mandatory. It is recommended that patients with bone metastases of renal cell cancer be treated with bisphosphonates approved for this indication. For urothelial carcinoma and other genitourinary tumors, the available data are not sufficient to give a recommendation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17091278     DOI: 10.1007/s00120-006-1229-x

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  12 in total

1.  Intravenous bisphosphonates and osteonecrosis.

Authors:  Martin S Greenberg
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2004-09

2.  Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer.

Authors:  Salvatore Ruggiero; Julie Gralow; Robert E Marx; Ana O Hoff; Mark M Schubert; Joseph M Huryn; Bela Toth; Kathryn Damato; Vicente Valero
Journal:  J Oncol Pract       Date:  2006-01       Impact factor: 3.840

3.  Treatment of osseous metastases in patients with renal cell carcinoma.

Authors:  Sung Taek Jung; Michelle A Ghert; John M Harrelson; Sean P Scully
Journal:  Clin Orthop Relat Res       Date:  2003-04       Impact factor: 4.176

4.  [Remineralization and pain relief in bone metastases after after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study].

Authors:  S Koswig; V Budach
Journal:  Strahlenther Onkol       Date:  1999-10       Impact factor: 3.621

5.  Solitary bony metastasis from renal cell carcinoma: significance of surgical treatment.

Authors:  Bruno Fuchs; Robert T Trousdale; Michael G Rock
Journal:  Clin Orthop Relat Res       Date:  2005-02       Impact factor: 4.176

Review 6.  [Bisphosphonate-associated osteonecrosis of the jaw].

Authors:  M H Abu-Id; Y Açil; J Gottschalk; T Kreusch
Journal:  Mund Kiefer Gesichtschir       Date:  2006-03

7.  Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.

Authors:  Aristotle Bamias; Efstathios Kastritis; Christina Bamia; Lia A Moulopoulos; Ioannis Melakopoulos; George Bozas; Vassiliki Koutsoukou; Dimitra Gika; Athanasios Anagnostopoulos; Christos Papadimitriou; Evagelos Terpos; Meletios A Dimopoulos
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

8.  Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.

Authors:  Allan Lipton; Ming Zheng; John Seaman
Journal:  Cancer       Date:  2003-09-01       Impact factor: 6.860

9.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

Authors:  Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Ming Zheng
Journal:  J Natl Cancer Inst       Date:  2004-06-02       Impact factor: 13.506

10.  Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.

Authors:  Eric J Small; Matthew R Smith; John J Seaman; Stephanie Petrone; Mildred Ortu Kowalski
Journal:  J Clin Oncol       Date:  2003-10-27       Impact factor: 44.544

View more
  1 in total

1.  [Therapy indications and options for skeletal metastases].

Authors:  M Schultheiss; A von Baer; F Gebhard; L Kinzl; M Arand
Journal:  Urologe A       Date:  2007-08       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.